Erythema Multiforme-Like Eruption Induced After Immune Checkpoint Inhibitor and Target Therapy in a Patient with Malignant Melanoma – A Case Report
Introduction. Erythema multiforme is an acute polyetiological hypersensitivity reaction characterized by polymorphic rashes of the skin and the mucous membranes. The triggering factors for the disease might be viral and bacterial infections, tumors, autoimmune connective tissue diseases, drugs. Immu...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sciendo
2025-04-01
|
| Series: | Acta Medica Bulgarica |
| Subjects: | |
| Online Access: | https://doi.org/10.2478/amb-2025-0025 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Introduction. Erythema multiforme is an acute polyetiological hypersensitivity reaction characterized by polymorphic rashes of the skin and the mucous membranes. The triggering factors for the disease might be viral and bacterial infections, tumors, autoimmune connective tissue diseases, drugs. Immune checkpoint inhibitors are used for the treatment of multiple oncological diseases but they often cause cutaneous immune-related adverse events. Pembrolizumab is a monoclonal antibody that blocks the programmed death 1 receptor and leads to T-cytotoxic lymphocyte activation. Vemurafenib is a BRAF inhibitor which is used for the treatment of metastatic melanomas positive for BRAF V600E mutation and blocks tumor cell proliferation. Both of these agents improve survival of melanoma patients, but the modified immune condition often results in severe side effects. |
|---|---|
| ISSN: | 2719-5384 |